Customers tell us they want peace of mind so that if a consumer has their beverage across multiple day parts, they will have a large margin before hitting tolerance levels. Why beverage brands need to brace themselves The thirst for GLP-1 medication only looks set to increase among consumers with the launch of unfussy, non-injectable formats A pill version of the appetite-suppressing drug, Wegovy, was unveiled by pharma giant Novo Nordisk in January Eli Lilly & Co is preparing to debut its own oral version, Orforglipron, post-FDA approval later this year The total GLP-1 pill market is forecast to leap from $3.2bn in 2025 to 34.3 bn in 2031, a CAGR of 48.4% (GlobalData) (Source GlobalData) GLP-1 drink NPD outside the box Although, its not just traditional food and beverage companies developing tailored NPD
Sulfotransferase 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation
Qsymia (phentermine-topiramate) comes in 3.75/23 mg, 7.5/46 mg, 11.25/69 mg, or 15/92 mg extended-release oral capsules, taken once daily
Emerging 2025 research suggests semaglutide (the drug in Ozempic and Wegovy) is associated with lower RA disease activity, less pain, and improved joint outcomes especially in patients who also carry excess weight
Check the plan year (ensure you are looking at the updated 2026 formulary) as coverage can change
